Intravaginal Flux Controlled Pump for Sustained Release of Macromolecules
- 2 May 2014
- journal article
- Published by Springer Nature in Pharmaceutical Research
- Vol. 31 (9) , 2344-2353
Abstract
To design a flux controlled pump (FCP) capable of 30-day, controlled release of macromolecules to the vaginal mucosa. The FCP is composed of a single chamber fabricated from a rigid thermoplastic with orifices and encloses a pellet of water-swellable polymer containing the drug substance. We performed testing both in vitro and in rabbits. To ensure vaginal retention in the rabbit, we designed and attached an oval shape-memory polyether urethane retainer to the FCP allowing for long-term intravaginal evaluation of a solid dosage form without invasive surgical implantation. The orifices and swelling properties of the polymer pellet control water entry for polymer hydration and expansion, and subsequent extrusion of the drug-containing gel from the orifice. A FCP device containing a pellet composed of hydroxypropyl cellulose compounded with a model macromolecule, achieved controlled in vitro release for 30 days with an average release rate of 24 ± 2 μg/day (mean ± SD) and range of 16 to 42 μg/day. We observed a slightly lower average release rate in vivo of 20 ± 0.6 μg/day (mean ± SD). The size of the orifice and nature of the swelling polymer controls the hydration rate and thereby macromolecule release rate and duration from this FCP.Keywords
This publication has 42 references indexed in Scilit:
- Adherence Support Approaches in Biomedical HIV Prevention Trials: Experiences, Insights and Future Directions from Four Multisite Prevention TrialsAIDS and Behavior, 2013
- Developing Multipurpose Reproductive Health Technologies: An Integrated StrategyAIDS Research and Treatment, 2013
- A 90-Day Tenofovir Reservoir Intravaginal Ring for Mucosal HIV ProphylaxisAntimicrobial Agents and Chemotherapy, 2012
- The Effectiveness of Carraguard, a Vaginal Microbicide, in Protecting Women against High-Risk Human Papillomavirus InfectionAntiviral Therapy, 2011
- Activity and Safety of Synthetic Lectins Based on Benzoboroxole-Functionalized Polymers for Inhibition of HIV EntryMolecular Pharmaceutics, 2011
- Design of a Potentd-Peptide HIV-1 Entry Inhibitor with a Strong Barrier to ResistanceJournal of Virology, 2010
- Vaginal delivery of the recombinant HIV-1 clade-C trimeric gp140 envelope protein CN54gp140 within novel rheologically structured vehicles elicits specific immune responsesVaccine, 2009
- Topically Applied Recombinant Chemokine Analogues Fully Protect Macaques from Vaginal Simian‐Human Immunodeficiency Virus ChallengeThe Journal of Infectious Diseases, 2009
- Intravaginal gene silencing using biodegradable polymer nanoparticles densely loaded with small-interfering RNANature Materials, 2009
- Scaleable manufacture of HIV-1 entry inhibitor griffithsin and validation of its safety and efficacy as a topical microbicide componentProceedings of the National Academy of Sciences, 2009